# US 2023/0398177 A1 · Compositions of anti-viral peptides and/or compounds and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398177 A1
- Document ID: US20230398177A1
- Status: Published application
- Kind: A1
- Application number: 18/249,926
- Filed: 2021-10-22
- Published: 2023-12-14
- Earliest claimed: 2020-10-22
- Assignees: The University of Hong Kong
- Applicants: The University of Hong Kong
- Inventors: Hanjun Zhao; Kwok-Yung Yuen
- Web page: https://patentgrep.com/patent/US20230398177A1

## CPC

- A61K 38/1729: {Cationic antimicrobial peptides, e.g. defensins}
- A61P 31/16: for influenza or rhinoviruses
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61P 31/14: for RNA viruses
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Broad spectrum antiviral peptides and compositions including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A (H1N1) pdm09 virus, avian influenza A (H7N9) virus, and the non-enveloped rhinovirus.

## Claims

### Claim 1

An antiviral agent comprising a multivalent peptide, wherein the multivalent peptide comprises three or more copies of one or a combination of peptides selected from the group consisting of P9R (SEQ ID NO:2) and P9R-like peptides derived from P9R,
wherein at least three of the peptides that comprise the multivalent peptide branch from one or more of the peptides that comprise the multivalent peptide.

### Claim 2 (depends on 1)

The antiviral agent of claim 1, wherein the multivalent peptide comprises six or more copies of the peptides,
wherein at least six of the peptides that comprise the multivalent peptide branch from one or more of the peptides that comprise the multivalent peptide.

### Claim 3 (depends on 1)

The antiviral agent of claim 1, wherein the multivalent peptide comprises eight or more copies of the peptides,
wherein at least eight of the peptides that comprise the multivalent peptide branch from one or more of the peptides that comprise the multivalent peptide.

### Claim 4 (depends on 1)

The antiviral agent of claim 1, wherein at least three of the peptides that branch from one or more of the peptides that comprise the multivalent peptide branch from a central point in the multivalent peptide.

### Claim 5 (depends on 1)

The antiviral agent of claim 1, wherein at least six of the peptides that branch from one or more of the peptides that comprise the multivalent peptide branch from a central point in the multivalent peptide.

### Claim 6 (depends on 1)

The antiviral agent of claim 1, wherein at least eight of the peptides that branch from one or more of the peptides that comprise the multivalent peptide branch from a central point in the multivalent peptide.

### Claim 7 (depends on 1)

The antiviral agent of claim 1, wherein the peptides that branch from one or more of the peptides that comprise the multivalent peptide branch from a central point in the multivalent peptide.

### Claim 8 (depends on 1)

The antiviral agent of claim 1, wherein the P9R-like peptides are characterized in that the P9R-like peptide inhibits endosomal acidification and retains virus binding as determined by an in vitro endosomal acidification,
optionally compared to a control, and/or a peptide-virus binding assay.

### Claim 9 (depends on 1)

The antiviral agent of claim 1, wherein the peptides that comprise the multivalent peptide each consist of P9R (SEQ ID NO:2).

### Claim 10 (depends on 1)

The antiviral agent of claim 1, wherein one or more of the peptides that comprise the multivalent peptide has a net positive charge of at least 5,
optionally wherein one or more of the peptides that comprise the multivalent peptide has a net positive charge of about 5.6.

### Claim 11 (depends on 1)

The antiviral agent of claim 1, wherein the peptides that comprise the multivalent peptide each has a net positive charge of at least 5,
optionally wherein the peptides that comprise the multivalent peptide each has a net positive charge of about 5.6.

### Claim at position 12

12-15. (canceled)

### Claim 16

An antiviral agent comprising P9R (SEQ ID NO:2) or a P9R-like peptide derived from P9R.

### Claim 17 (depends on 16)

The antiviral agent of claim 16, wherein the P9R-like peptide is characterized in that the P9R-like peptide inhibits endosomal acidification and retains virus binding as determined by an in vitro endosomal acidification,
optionally compared to a control, and/or a peptide-virus binding assay.

### Claim 18 (depends on 16)

The antiviral agent of claim 16, consisting of P9R (SEQ ID NO:2).

### Claim 19 (depends on 16)

The antiviral agent of claim 16, wherein the antiviral agent has a net positive charge of at least 5,
optionally wherein the antiviral agent has a net positive charge of about 5.6.

### Claim at position 17

20-21. (canceled)

### Claim 22 (depends on 1)

A composition comprising a therapeutically effective amount of the antiviral agent of claim 1 and a pharmaceutically acceptable carrier.

### Claim 23

An antiviral composition comprising arbidol, chloroquine, and camostat.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the antiviral agent inhibits antiviral replication in the subject.

### Claim 25 (depends on 22)

The composition of claim 22, wherein the composition is a unit dosage form.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the unit dosage form is a tablet, a capsule, or a form suitable for intranasal or pulmonary delivery.

### Claim 27

(canceled)

### Claim 28 (depends on 25)

The composition of claim 25, wherein the unit dosage form is an injectable form,
optionally wherein the composition further comprises a pharmaceutically acceptable carrier for injection to a human.

### Claim 29 (depends on 22)

A method of treating a viral infection in a subject in need thereof, the method comprising
administering an effective amount of the composition of claim 22, to the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the infection is caused by a respiratory virus,
optionally wherein the virus is selected from the group consisting of zika virus, enterovirus-A7, ebola virus, influenza virus, SARS-CoV-2, SARS-CoV, MERS-CoV, the A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

### Claim 31 (depends on 29)

The method of claim 29, wherein the infection is caused by a pH-dependent virus that requires endosomal acidification for virus-host membrane fusion.

### Claim 32 (depends on 29)

The method of claim 29, wherein the composition is administered parenterally orally, intranasally, or by pulmonary administration.

### Claim at position 29

33-34. (canceled)
